Twist Bioscience officer sells 844 shares for taxes

Twist Bioscience Corp officer Dennis Cho reported an open-market sale of 844 shares of common stock at $46.7098 per share.

Rhea-AI Filing Summary

Twist Bioscience Corp officer Dennis Cho reported an open-market sale of 844 shares of common stock at $46.7098 per share. According to the filing, the shares were sold to cover tax withholding owed on vesting restricted stock units under a mandatory “sell to cover” arrangement, rather than a discretionary trade. After this transaction, Cho directly held 138,682 shares.

Insider Trade Summary

Net Seller: 844 shares

Net Sell 1 txn

Insider Cho Dennis

Role See Remarks

Sold 844 shs ($39K)

Type	Security	Shares	Price	Value
Sale	Common Stock	844	$46.7098	$39K

Holdings After Transaction: Common Stock — 138,682 shares (Direct)

Footnotes (2)

1. F1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
2. F2. Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Twist Bioscience (TWST) report for Dennis Cho?

Twist Bioscience reported that officer Dennis Cho sold 844 shares of common stock at $46.7098 per share. The filing describes this as an open-market sale linked to equity compensation vesting, not a discretionary decision to reduce his investment in the company.

Why did Dennis Cho sell 844 Twist Bioscience (TWST) shares?

The 844 shares were sold to cover tax withholding obligations from vesting restricted stock units. The company’s equity plans require a mandatory “sell to cover” transaction, so these sales are for taxes and are not discretionary trading decisions by Dennis Cho.

How many Twist Bioscience (TWST) shares does Dennis Cho hold after this Form 4?

After the tax-related sale, Dennis Cho directly holds 138,682 shares of Twist Bioscience common stock. The filing notes this balance includes shares acquired through the company’s Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(d) and Rule 16b-3(c).

What was the price for Dennis Cho’s Twist Bioscience (TWST) share sale?

The 844 shares of Twist Bioscience common stock were sold at $46.7098 per share. This price applies specifically to the tax-withholding “sell to cover” transaction related to vesting restricted stock units disclosed in the Form 4 filing for Dennis Cho.

Is Dennis Cho’s Twist Bioscience (TWST) share sale considered a discretionary trade?

No. The filing states the sale was mandated by Twist Bioscience’s equity incentive plans as a “sell to cover” for tax withholding. Because of this structure, the transaction does not represent a discretionary trading decision by Dennis Cho in the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/25/2026 - 04:05 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cho Dennis

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/23/2026		S		844(1)	D	$46.7098	138,682(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

2. Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Remarks:

Senior Vice President, Chief Legal Officer & Corporate Secretary

	/s/ Kendra Fox, as Attorney-in-Fact for Dennis Cho	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.